Abstract: NBI Biosciences is making significant contributions to advancing breakthroughs in oral insulin. Type 2 Diabetes (T2D) is influenced also by Dysbiosis which impairs glucose regulation, while diet, obesity, and epigenetic changes worsen insulin resistance. Effective management strategies include microbiome therapies, better diets, and personalized treatments.
DownloadAbstract: Diabetes treatment has evolved over the years, but as global rates rise, especially in developing countries, more effective and less burdensome therapies are needed. Innovations in diabetes care, ranging from new classes of drugs to gene-editing technologies and advanced delivery systems, hold the potential to revolutionize how the disease is managed. These innovations are moving from concept to clinical trials, promising more personalized, effective, and patient-friendly treatments.
DownloadAbstract: Diabetes afflicts 540 millions of patients worldwide; most of them develop chronic diabetes that requires insulin injections to stabilize blood glucose. Though injections are the most convenient mode of delivery, oral insulin is not feasible because the digestive system breaks down insulin proteins in the stomach and intestines, preventing proper absorption into the bloodstream. This makes the insulin ineffective in regulating blood sugar levels when taken orally. These days, scientific research projects are more directed towards innovative approaches with polymer-based stabilization for developing orally administrable insulin preparations more effectively.
DownloadAbstract: In the midst of the Covid-19 pandemic, there is another pandemic that has been hiding in plain sight. Mental health diseases are rapidly growing, and the United Nations predicts that mental health ailments, such as depression, will be the number one disease burden worldwide, by 2030.
DownloadAbstract: Type 2 diabetes mellitus is characterized by Insulin resistance and β-cell dysfunction which leads to the imbalance in homeostasis. Globally, more than 90% of adult diabetics suffer from Type 2 diabetes. The sharp increase in the number of children and adolescent Type 2 diabetics is a matter of grave concern. Both genetic and environmental factors lead to this multifactorial form of diabetes. While early detection would resolve most of the challenges posed by this form, several populations across the globe remain unaware of symptoms and face difficulty in accessing medical support.
DownloadAbstract: The global oral insulin market is projected to grow from USD 1.9 billion in 2023 to USD 12.8 billion by 2030, offering a transformative alternative to injections in diabetes care. Nanoparticle delivery systems are advancing the field and oral insulin holds significant potential in regions such as the U.S., China, India, Europe, Japan, Latin America, the MENA and Australia / New Zealand, with the promise to revolutionize treatment and improve patient outcomes.
DownloadAbstract: Plant-derived medicines are projected to expand at a compound annual growth rate (CAGR) of 9% from 2021 to 2028, having already seen growth exceeding 9.0% in recent years fueled by a strong focus on preventative health care and nutritional medicines. India presents a unique opportunity to satisfy the rising demand, thanks to its rich natural biodiversity, featuring over 50,000 plant species and the advantage of low-cost production. The worldwide market for the Asia Pacific region holds more than 31% of this market share and is anticipated to maintain this leadership.
DownloadAbstract: Insulin, the blood sugar controlling peptide hormone, requires to be supplemented to diabetics intravenously to maintain healthy glucose levels. While the manufacturing of insulin and its analogs have been successfully achieved by many, the storage of the recombinant drug in its viable form at higher temperatures is a matter of constant concern.
Download